Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.

Hiroyuki Tsutsui,Hiroyuki Sakamaki,Shin-Ichi Momomura,Yasushi Sakata,Yutaro Kotobuki,Stephan Linden,Odette S Reifsnider,Pal Rakonczai,Matthew Stargardter,Tatsunori Murata,Tetsuaki Hirase,Daisuke Nitta

Journal of cardiology（2023）

Cited 2|Views24
No score
Abstract
Empagliflozin was demonstrated to be cost-effective for HFrEF patients in Japan based on the EMPEROR-Reduced trial data.
More
Translated text
Key words
Cost-effectiveness analysis,EMPEROR-reduced,Empagliflozin,Heart failure with reduced ejection fraction
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined